Myeloproliferative Neoplasm Quality of Life

~ International Study Group ~

For MPN-QOL Investigators

For MPN Healthcare Providers

Decrease Font Size
Increase Font Size

SYMPTOMS Trial: Symptoms Yielded in Myelofibrosis Patients after Transplant as Objectified by MPN-SAF TSS

The SYMPTOMS trial aims to compare symptom burden as measured by the MPN-SAF Total Symptom Score (TSS-10) between MF patients undergoing allo-SCT and MF patients not undergoing allo-SCT at each post transplant (or alternative treatment initiation) time point.

Patients enrolling in this trial must:

  1. Have myelofibrosis (MF) including primary MF, Post-ET, or Post–PV MF.
  2. Be potential stem cell transplant candidates and undergoing HLA haplotyping.
  3. Be willing to complete a packet of metrics (see documents below) at day 0, day 30, day 100 and 1 year post-allo-transplant and sign informed consent prior to enrollment. Patients not undergoing allo-transplant will complete the same metrics at day 0, day 30, day 100 and 1 year post initiation of standard medical therapy (aspirin, hydroxyurea, anagrelide, interferon, busulfan, melphalan, cladribine, thalidomide, lenalidomide, prednisone, danazol, ruxolitinib, and/or phlebotomy) or observation. Metric packages are available in English, Italian, Swedish, French, German, Dutch, and Spanish.


Login for Coinvestigators

Last Updated Thursday, July 18, 2019 - 06:16 AM.